Why the Assessment Comes Before the Injection
A wide or square lower face is not one problem but at least three that look alike in a mirror: an enlarged masseter muscle, a broad mandibular angle (bone), and buccal or jowl fat. Botulinum toxin acts on the first and does nothing to the other two, which is why the width of the lower face is sorted before any injection is planned.
The treatment is commonly searched for as “masseter botox” or “jaw botox”. Here it is called masseter BTX, or botulinum toxin, because the medicine is the active ingredient rather than a brand. Several botulinum toxin type A products are HSA-registered in Singapore; all are prescription-only medicines administered by a registered doctor. This article is the educational companion to the jaw BTX and face slimming treatment page.
Key Facts
- Medicine
- Botulinum toxin type A: a 150 kDa neurotoxin (100 kDa heavy chain, 50 kDa light chain), reconstituted in preservative-free 0.9% sodium chloride
- Mechanism
- The light chain cleaves SNAP-25, a 25 kDa SNARE protein; acetylcholine is not released at the neuromuscular junction and the muscle thins from disuse
- Reversibility
- Reversible: the nerve terminal rebuilds its release machinery; no muscle tissue is removed
- Target
- The masseter muscle belly, below the zygomatic arch and above the mandibular border, injected intramuscularly
- Structures avoided
- The risorius and zygomaticus (smile muscles), and the parotid duct crossing the upper masseter
- Boundary respected
- The anterior border of the masseter: injection points stay behind it so the smile is untouched
- Nerve supply
- Masseteric nerve, mandibular division of the trigeminal nerve (CN V3); one of the four muscles of mastication
- Classification
- Prescription-only medicine in Singapore, administered by a registered medical practitioner; HSA-registered botulinum toxin type A products
What the Masseter Is
The masseter is the thick, rectangular muscle felt at the angle of the jaw on clenching. It runs from the zygomatic arch to the outer surface of the mandibular ramus and angle, in superficial, middle and deep layers, and it closes the jaw. Like any skeletal muscle it enlarges with work: clenching, night-time grinding, chewing gum, tough food, or a one-sided chewing habit that grows one side more than the other. Because it sits directly under the skin at the angle, its size sets the outline of the lower face.
Muscle, Bone or Fat: the Clench Test
Three structures can make the lower face wide, and they are sorted at consultation:
- Masseter hypertrophy. Clench hard and the angle of the jaw bulges and firms under the fingers; relax and it softens. This is what botulinum toxin acts on.
- Mandibular angle bone. The angle is broad or flared by skeletal shape. It feels hard whether clenched or relaxed, and no injection changes it. A bone-dominant jaw is a square jaw question with a different answer.
- Buccal or jowl fat. Softness in front of the masseter or along the jawline that does not firm on clenching. Fat is a volume question, addressed by buccal fat approaches for the round face or, under the jaw, by submental fat treatment.
Most faces are a mix. The clench test shows how much of the width is muscle, and when the muscle contributes little, the honest advice is that this treatment is not the right one.
“Toxin weakens a muscle. It does nothing to bone and nothing to fat — so the first question is never the dose, but which of the three is making the jaw wide.”
Dr Sin YongOn assessing a wide lower face
How Botulinum Toxin Type A Works
A nerve tells a muscle to contract by releasing acetylcholine at the neuromuscular junction, from vesicles that fuse with the nerve terminal using the SNARE proteins. Botulinum toxin type A is taken up into the terminal, and its light chain, a zinc-dependent enzyme, cleaves one of those proteins, SNAP-25. Without intact SNAP-25 the vesicles cannot fuse, acetylcholine is not released, and the muscle fibres are no longer told to contract.
The slimming follows from that. A muscle that is not working undergoes atrophy of disuse, the way a limb thins inside a cast; the masseter loses bulk because it is resting, not because anything has been removed. The block is reversible: the terminal rebuilds its release machinery, function returns, and the muscle can rebuild if the clenching habit continues, which is why the plan is individual and reviewed over time.
Who It Suits, and Who It Does Not
Masseter BTX is directed at adults whose lower-face width is driven mainly by masseter hypertrophy on examination, and at people whose masseters are overworked by bruxism or habitual clenching, whether or not they also want a slimmer outline.
It is not the right treatment when the width is bone-dominant, when the softness is jowl or buccal fat, or when the cheeks are already hollow and a smaller masseter would leave the face gaunt. It is not given during pregnancy or breastfeeding. It is assessed with particular care, and often declined, in neuromuscular disorders such as myasthenia gravis, in anyone taking aminoglycoside antibiotics or other medicines that affect neuromuscular transmission, and where there is infection at the site or hypersensitivity to a botulinum toxin product.
Bruxism and Jaw Tension: the Medical Indication
Bruxism is the grinding or clenching of the teeth, often at night and often unnoticed until a partner hears it or a dentist sees the wear. The masseter does most of that work, and its overuse is linked to jaw ache on waking, tension-type headache, tooth wear and strain on the temporomandibular joint. Chronic clenching is also one of the commonest routes to masseter hypertrophy, which is why the medical and aesthetic questions so often arrive together.
Botulinum toxin reduces the force the masseter can generate, and so the load that grinding places on the teeth and the joint. It does not treat the cause of bruxism, which may be stress, sleep disturbance, airway problems or medication, and it does not replace a night guard. Where bruxism is the indication, dental review sits alongside the plan and the aim is comfort and load rather than appearance.
The Assessment
The consultation begins with the clench test, the masseter palpated on each side at rest and under maximal clench so that thickness, where the bulk sits, and any asymmetry are recorded. The anterior border of the masseter is located, because the smile muscles lie in front of it. The mandibular angle, chin, fat and skin are examined too, since a jaw sometimes reads as wide because the chin is short, in which case chin enhancement is the more relevant discussion. Medical, medication, dental and jaw-joint history is taken.
What the Appointment Involves
Injection points are marked within a zone bounded above by a line from the tragus of the ear to the corner of the mouth, below by the mandibular border, and in front by the anterior border of the masseter. Below the tragus–commissure line the needle stays clear of the parotid duct, which crosses the upper part of the muscle; behind the anterior border it stays clear of the risorius and zygomaticus, which lift the corner of the mouth. The toxin is placed intramuscularly into the belly of the muscle, at more than one point and depth so that deep and superficial layers are both reached, with the dose divided between sides according to the examination.
Recovery
Recovery varies. A mild ache in the muscle, small bruises at the injection points and a heaviness when chewing tough food are normal in the early period. Massaging the area is avoided so that toxin is not pushed toward the smile muscles or the parotid. Symptoms that warrant review rather than waiting are a lopsided smile, difficulty swallowing or speaking, a new dry mouth, or a bulge at the angle of the jaw on chewing. A review is planned so that asymmetry can be assessed and, where appropriate, addressed.
Risks Stated Plainly
- Smile asymmetry. Toxin that reaches the risorius or zygomaticus lifts the corner of the mouth less on that side; this is why the anterior border of the masseter is respected.
- Chewing fatigue. Hard or chewy food is more tiring while the effect is present; over-dosing makes this pronounced.
- Paradoxical bulging. If the deep fibres are weakened but the superficial layer is not, the superficial fibres bunch on clenching and the angle looks bigger; it is addressed by treating the layer that was missed.
- Sunken cheeks. In a thin face, over-treatment removes support under the skin at the angle and the lower cheek can look hollow; a reason to decline or plan conservatively.
- Dry mouth. Toxin in the parotid gland or its duct reduces saliva on that side.
- Bruising, tenderness, headache and, rarely, flu-like symptoms. Very rarely toxin spreads beyond the injected area; this is why it is a prescription medicine given by a registered doctor.
How It Differs From the Adjacent Options
These are different mechanisms for different questions, not competing versions of one treatment:
- Chin filler adds structure: a hyaluronic acid gel lengthens or projects the chin so the lower face reads as a taper. It puts volume in where masseter BTX takes muscle work out; the V-shape combination is covered in the guide to chin fillers and the V-shape.
- Buccal fat removal is surgical: the buccal fat pad is removed through an incision inside the mouth. It changes the fat in front of the masseter and does nothing to the muscle.
- Jawline filler adds definition along the mandibular border. It is about the edge of the jaw rather than its width, and in a masseter-dominant face it can make the jaw look heavier.
- HIFU delivers focused ultrasound to fixed depths of 1.5, 3.0 and 4.5 mm to heat the dermis and SMAS. It is directed at skin laxity along the jawline, not at muscle.
- BTX elsewhere on the face uses the same molecule to relax the muscles that fold skin into lines; see the wrinkle-prevention BTX page.
For an overview of the jaw treatment itself, see the jaw BTX Singapore guide.
What Determines the Cost
Cost is set out at consultation, once the examination has answered the questions above. The factors are the thickness of the masseter on each side, since the dose follows the muscle; whether the sides differ; whether the indication is bruxism, slimming or both; the formulation used; whether chin enhancement or another treatment is combined; and how the plan is staged and reviewed. Treatment on the jaw BTX and face slimming page is planned individually, and no figure is quoted before the assessment.
Related Pages
- Jaw BTX and face slimming — the treatment page
- Square jaw and the masseter
- Chin enhancement
- Buccal fat and the round face
- Double chin treatment
- Wrinkle-prevention BTX
- HIFU
- Jaw BTX Singapore guide
- Chin fillers and the V-shape
Ready to Book a Consultation?
All treatments performed personally by Dr Sin Yong at Orchard Road, Singapore.
WhatsApp +65 8023 7170Frequently Asked Questions
Yes. Jaw slimming injections, jaw BTX and masseter BTX all describe botulinum toxin type A injected into the masseter muscle at the angle of the jaw. The treatment slims the lower face by resting the muscle so that it loses bulk through disuse. It has no effect on the jawbone or on fat, so the term jaw slimming is accurate for a muscle-dominant jaw and misleading for a bone-dominant one.
Clench the back teeth hard while pressing two fingers over the angle of the jaw. A muscle-dominant jaw bulges and firms under the fingers and softens on relaxing; a bone-dominant jaw feels equally hard in both states and its outline does not change. Fat in front of the jaw stays soft throughout. Most faces are a mixture, and the proportion is assessed at consultation before any injection is planned.
Botulinum toxin injected into the masseter reduces the force the muscle can generate, which lowers the load that grinding and clenching place on the teeth and the temporomandibular joint. It does not remove the underlying cause of bruxism, such as stress, disturbed sleep or airway problems, and it does not replace a night guard from a dentist, which protects the tooth surfaces mechanically. Dental review is part of the plan when bruxism is the indication.
It should not, when the injections stay behind the anterior border of the masseter. The risorius and zygomaticus muscles that lift the corner of the mouth lie just in front of that border, and toxin placed or spreading into them causes a lopsided smile on that side. The border is located by palpation at each visit, injection points are kept behind it, and the area is not massaged afterwards. A smile change is a reason for review.
It can, in a thin face or with over-treatment. The masseter supports the skin at the angle of the jaw, and if a slim face loses that support the lower cheek can look hollow rather than slim. This is one of the reasons the whole lower face, including buccal fat and cheek volume, is examined before the dose is set, and one of the reasons the treatment is sometimes declined.
Paradoxical bulging is a lump that appears at the angle of the jaw on clenching after masseter BTX. It happens when the deep fibres of the muscle have been weakened but the superficial layer has not, so the superficial fibres bunch outward when the jaw closes. It is not permanent and is addressed at review by placing toxin in the layer that was missed. Injecting at more than one depth is intended to avoid it.
Yes. The masseter is one of four muscles of mastication, and the temporalis and medial pterygoid continue to close the jaw. What people notice is tiredness when chewing tough or chewy food while the effect is present, which is more pronounced if the dose is high for the muscle. Difficulty swallowing or speaking is not expected and warrants review. Dose is set to the muscle found on examination, not to a standard figure.
Botulinum toxin is not given during pregnancy or breastfeeding, where there is infection at the injection site, or to anyone with a known hypersensitivity to a botulinum toxin product. It is assessed with care, and often declined, in neuromuscular disorders such as myasthenia gravis or Lambert-Eaton syndrome and in people taking aminoglycoside antibiotics or other medicines that affect neuromuscular transmission. It is also not the right treatment when the jaw width is bone or fat rather than muscle.
Yes. Botulinum toxin type A is a prescription-only medicine in Singapore. Products used in clinics are registered with the Health Sciences Authority, and the injection is administered by a registered medical practitioner after a consultation that records the indication, the examination findings and the dose given. Potency units are specific to the assay of each product, so a unit of one formulation is not equivalent to a unit of another.
It can, and the combination is often discussed for a V-shaped lower face. The two work by different mechanisms: masseter BTX rests the muscle at the angle of the jaw so that it loses bulk, while chin filler adds hyaluronic acid gel to lengthen or project the chin so that the lower face tapers. Whether both are relevant depends on what the examination finds; a short chin with a muscle-dominant jaw is the usual case.
References
- Padda IS, Tadi P. Botulinum Toxin. StatPearls [Internet], NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK557387/
- Corcoran NM, Goldman EM. Anatomy, Head and Neck, Masseter Muscle. StatPearls [Internet], NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK539869/
- Lal SJ, Sankari A, Weber KK. Bruxism Management. StatPearls [Internet], NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK482466/
- Rauso R, Lo Giudice G, Tartaro G, et al. Botulinum toxin type A injections for masticatory muscles hypertrophy: a systematic review. J Craniomaxillofac Surg. 2022;50(1):7-18. https://pubmed.ncbi.nlm.nih.gov/34620536/
- Carruthers J, Burgess C, Day D, et al. Consensus Recommendations for Combined Aesthetic Interventions in the Face Using Botulinum Toxin, Fillers, and Energy-Based Devices. Dermatol Surg. 2016;42(5):586-97. https://pubmed.ncbi.nlm.nih.gov/27100962/
